Inovio Gets Authorization For Phase 3 Trial Of INO-4800 COVID -19 Vaccine Candidate In India

Inovio Pharmaceuticals, Inc. (INO) Wednesday said it has received authorization from India's Central Drugs Standard Control Organization to proceed with the Phase 3 segment of the global Phase 2/3 trial, INNOVATE, in India for INO-4800. The trial will evaluate the efficacy of INO-4800 in a two-dose regimen of 2.0 mg per dose.

Earlier, the company has received regulatory authorization in Brazil, the Philippines, Mexico, and Colombia.

The study in India plans to one month apart administration, in 2-to-1 randomization in men and non-pregnant women 18 years of age and older. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed symptomatic COVID-19.

The biotechnology company that designs DNA medicines said it will be partnering with Advaccine Biopharmaceuticals Suzhou Co., Ltd. or Advaccine to conduct the INNOVATE Phase 3 segment in multiple countries in Latin America, Asia, and Africa.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT